cannabis indica

Índice completo — página 71 de 77

Estudos 7.001 a 7.100 de 7.640, ordenados do mais recente ao mais antigo — nesta página, publicações de 2006 a 2005. Para buscar por termo ou combinar filtros, use o acervo com busca.

Estudos 7.001 a 7.100

  1. 2006

    Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes.

    FavorávelEstudo em AnimaisEstresse OxidativoDoenças NeurodegenerativasDiabetes+1
  2. 2006

    Olfactory stimulation with scent of lavender oil affects autonomic neurotransmission and blood pressure in rats.

    FavorávelEstudo em AnimaisDoenças Cardiovasculares (DCV)Hipertensão Arterial
  3. 2006

    Overexpression Of Cannabinoid Receptors CB1 And CB2 Correlates With Improved Prognosis Of Patients With Hepatocellular Carcinoma

    FavorávelEstudo LaboratorialCâncerCâncer — Fígado
  4. 2006

    Perinatal exposure to delta(9)-tetrahydrocannabinol alters heroin-induced place conditioning and fos-immunoreactivity

    DesfavorávelEstudo em AnimaisDependência — OpioidesAlterações Cerebrais NeonataisTetraidrocanabinol (THC)
  5. 2006

    Peripheral cannabinoid receptor, CB2, regulates bone mass

    FavorávelEstudo em AnimaisCondições GeriátricasOsteoporoseLongevidadeCanabinoides Sintéticos HU-x
  6. 2006

    Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDor — CrônicaTetraidrocanabinol (THC)THC:CBD Farmacêutico+3
  7. 2006

    Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis

    DesfavorávelEnsaio ClínicoPsicose
  8. 2006

    Rimonabant for overweight or obesity

    FavorávelMetanálise ClínicaObesidadeCanabinoides Sintéticos SR-x
  9. 2006

    Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.

    FavorávelMetanáliseDorEsclerose MúltiplaDor — Neuropatia PeriféricaTetraidrocanabinol (THC)THC:CBD Farmacêutico
  10. 2006

    Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against 'morning sickness'.

    FavorávelMetanáliseNáusea e VômitoEnjoo Matinal na Gestação
  11. 2006

    Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine.

    FavorávelEnsaio Clínico Duplo-CegoDorDependência QuímicaDependência — OpioidesTetraidrocanabinol (THC)+1
  12. 2006

    The cannabinergic system as a target for anti-inflammatory therapies.

    FavorávelMetanáliseDoenças Cardiovasculares (DCV)Esclerose MúltiplaDiabetesEndocanabinoide (não especificado)Canabinoide Sintético (não especificado)+5
  13. 2006

    The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism

    FavorávelEstudo LaboratorialCâncerCâncer — MamaCanabinoides Sintéticos SR-x
  14. 2006

    The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).

    FavorávelEnsaio Clínico Duplo-CegoEsclerose MúltiplaInfecção Urinária
  15. 2006

    The effect of terpene concentrations on the skin penetration of diclofenac sodium.

    FavorávelEstudo LaboratorialDoenças de PelePsoríaseEczema
  16. 2006

    The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic?

    DesfavorávelMetanáliseEfeitos Adversos da CannabisEfeitos Adversos do MDMA
  17. 2006

    The emerging role of cannabinoid neuromodulators in symptom management.

    FavorávelMetanálise ClínicaDorCâncerNáusea e VômitoTHC Farmacêutico+2
  18. 2006

    The Endocannabinoid System in Ageing: A New Target for Drug Development

    FavorávelMetanáliseDisfunção CognitivaCondições GeriátricasLongevidadeEndocanabinoide (não especificado)+1
  19. 2006

    The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia.

    FavorávelMetanáliseDoenças Cardiovasculares (DCV)InfartoCardiopatia CrônicaAnandamida (AEA)Tetraidrocanabinol (THC)+3
  20. 2006

    The Non-psychoactive Cannabidiol Triggers Caspase Activation And Oxidative Stress In Human Glioma Cells

    FavorávelEstudo LaboratorialCâncerCâncer — Cérebro
  21. 2006

    The Prevalence of Marijuana Smoking in Young Adults with Sickle Cell Disease A Longitudinal Study

    InconclusivoMetanáliseDoença Falciforme
  22. 2006

    The prevalence of marijuana smoking in young adults with sickle cell disease: a longitudinal study.

    InconclusivoMetanáliseDoença Falciforme
  23. 2006

    The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells

    FavorávelEstudo LaboratorialCâncerCâncer — CérebroCâncer — MetastáticoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  24. 2006

    The treatment of spasticity with Δ9-tetrahydrocannabinol in persons with spinal cord injury.

    FavorávelEnsaio Clínico Duplo-CegoLesões da Medula EspinhalTHC Farmacêutico
  25. 2006

    Therapeutic action of cannabinoid on axonal injury induced by peroxynitrite.

    FavorávelEstudo em AnimaisEsclerose MúltiplaTraumatismo CranioencefálicoCanabinoides Sintéticos HU-x
  26. 2006

    Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus.

    FavorávelEnsaio ClínicoPruridoOutros Compostos Relacionados
  27. 2006

    Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions.

    FavorávelMetanáliseHepatite
  28. 2006

    Treatments for Chronic Pain in Persons With Spinal Cord Injury: A Survey Study

    FavorávelMetanáliseDorDor — CrônicaLesões da Medula Espinhal
  29. 2006

    Tuberculosis Outbreak in Marijuana Users, Seattle, Washington, 2004

    InconclusivoMetanáliseTuberculose
  30. 2006

    Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways

    FavorávelEstudo LaboratorialÁcido Tetraidrocanabinólico (THC-a)
  31. 2006

    Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation

    FavorávelEstudo em AnimaisInflamaçãoDII — Doença Inflamatória IntestinalAnandamida (AEA)Endocanabinoide (não especificado)+2
  32. 2006

    Δ9-Tetrahydrocannabinol Inhibits Cell Cycle Progression In Human Breast Cancer Cells Through Cdc2 Regulation

    FavorávelEstudo LaboratorialCâncerCâncer — MamaTetraidrocanabinol (THC)
  33. 2005

    (+)- And (-)-borneol: efficacious positive modulators of GABA action at human recombinant alpha1beta2gamma2L GABA(A) receptors

    FavorávelEstudo LaboratorialDorDor — Aguda
  34. 2005

    [Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication]

    FavorávelEnsaio Clínico Duplo-CegoDorEsclerose MúltiplaDor — Síndrome da Dor CentralTHC Farmacêutico
  35. 2005

    A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia

    InconclusivoMetanáliseDependência QuímicaPsicoseEsquizofreniaHidrolase de Amidas de Ácidos Graxos (FAAH)+1
  36. 2005

    A Role For Cannabinoid CB1 Receptors In Mood And Anxiety Disorders

    FavorávelMetanáliseAnsiedadeTetraidrocanabinol (THC)
  37. 2005

    Ajulemic Acid (IP-751): Synthesis, Proof Of Principle, Toxicity Studies, And Clinical Trials

    FavorávelEstudo em AnimaisArtriteArtrite — OsteoartriteCanabinoide Sintético (não especificado)
  38. 2005

    Alcohol, marijuana, cocaine use, and relationship quality among HIV serodiscordant male couples

    InconclusivoMetanáliseViolência Doméstica
  39. 2005

    AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation

    FavorávelEstudo em AnimaisLesões da Medula EspinhalCanabinoides Sintéticos AM-x
  40. 2005

    Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

    FavorávelEstudo em AnimaisFibroseFibrose — Hepática (Cirrose)Anandamida (AEA)Tetraidrocanabinol (THC)+3
  41. 2005

    Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat

    FavorávelEstudo LaboratorialDorInflamaçãoDor — CrônicaTetraidrocanabinol (THC)Canabinoides Sintéticos WIN-x+4
  42. 2005

    Antileishmanial Activity of the Terpene Nerolidol

    FavorávelEstudo LaboratorialInfecções Bacterianas
  43. 2005

    Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods

    DesfavorávelMetanálisePsicoseGestaçãoAlterações Cerebrais Neonatais
  44. 2005

    Biphasic Effects of Geranylgeraniol, Teprenone, and Phytol on the Growth of Staphylococcus aureus.

    FavorávelEstudo LaboratorialInfecção por Estafilococos
  45. 2005

    Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa

    InconclusivoMetanáliseAnorexia (perda de apetite)Anorexia NervosaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  46. 2005

    Cannabidiol Inhibits Human Glioma Cell Migration Through A Cannabinoid Receptor-independent Mechanism

    FavorávelEstudo LaboratorialCâncerCâncer — CérebroCanabinoides Sintéticos SR-x
  47. 2005

    Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.

    FavorávelEstudo em AnimaisDiabetes
  48. 2005

    Cannabimimetic effects of osteopathic manipulative treatment.

    FavorávelEnsaio ClínicoDorAnsiedadeDor — CrônicaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  49. 2005

    Cannabinoid CB2 Receptor Agonist Activity in the Hindpaw Incision Model of Postoperative Pain

    FavorávelEstudo em AnimaisDorDor — AgudaCanabinoide Sintético (não especificado)Canabinoides Sintéticos AM-x+1
  50. 2005

    Cannabinoid hyperemesis with the unusual symptom of compulsive bathing

    DesfavorávelMetanáliseSíndrome da Hiperêmese Canabinoide
  51. 2005

    Cannabinoid influence on cytokine profile in multiple sclerosis

    InconclusivoEnsaio Clínico Duplo-CegoEsclerose MúltiplaTetraidrocanabinol (THC)
  52. 2005

    Cannabinoid Receptor As A Novel Target For The Treatment Of Prostate Cancer

    FavorávelEstudo LaboratorialCâncerCâncer — PróstataCanabinoides Sintéticos WIN-xCanabinoides Sintéticos SR-x
  53. 2005

    Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma

    FavorávelEstudo LaboratorialCâncerCâncer — LinfomaAnandamida (AEA)Canabinoides Sintéticos WIN-x+1
  54. 2005

    Cannabinoid receptor type 2 gene is associated with human osteoporosis.

    FavorávelEstudo em AnimaisOsteoporose
  55. 2005

    Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus.

    FavorávelEstudo em AnimaisAnorexia (perda de apetite)Anandamida (AEA)Canabinoides Sintéticos AM-x+1
  56. 2005

    Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.

    FavorávelMetanáliseTranstorno BipolarAnandamida (AEA)THC Farmacêutico+1
  57. 2005

    Cannabinoids in multiple sclerosis -- therapeutically reasonable?

    FavorávelMetanáliseEsclerose Múltipla
  58. 2005

    Cannabinoids Promote Embryonic And Adult Hippocampus Neurogenesis And Produce Anxiolytic- And Antidepressant-like Effects

    FavorávelEstudo em AnimaisAnsiedadeDepressãoDisfunção CognitivaCanabinoides Sintéticos HU-x+2
  59. 2005

    Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

    FavorávelEstudo em AnimaisDoença de ParkinsonCanabinoides Sintéticos HU-x
  60. 2005

    Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.

    FavorávelEstudo LaboratorialCâncerCâncer — CérebroTetraidrocanabinol (THC)Canabinoides Sintéticos WIN-x
  61. 2005

    Cannabinoids: between neuroprotection and neurotoxicity

    FavorávelMetanáliseDoenças NeurodegenerativasEndocanabinoide (não especificado)2-Araquidonoilglicerol (2-AG)
  62. 2005

    Cannabinol Delays Symptom Onset In SOD1 (G93A) Transgenic Mice Without Affecting Survival

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasEsclerose Lateral Amiotrófica (ELA)Canabinol (CBN)
  63. 2005

    Cannabis and tobacco smoke are not equally carcinogenic

    InconclusivoMetanáliseCâncerCâncer — Pulmão
  64. 2005

    Cannabis as a precipitant of cardiovascular emergencies

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDoenças Cardiovasculares (DCV)Infarto+1
  65. 2005

    Cannabis as a risk factor for psychosis: systematic review

    DesfavorávelMetanálise ClínicaPsicoseEsquizofrenia
  66. 2005

    Cannabis sativa and dystonia secondary to Wilson's disease.

    FavorávelMetanáliseDoença de WilsonTetraidrocanabinol (THC)Canabicromeno (CBC)
  67. 2005

    Cannabis use in HIV for pain and other medical symptoms

    FavorávelMetanáliseDorDor — Neuropatia PeriféricaHIV/AIDS
  68. 2005

    Cannabis use in sickle cell disease: a questionnaire study.

    FavorávelMetanáliseDoença Falciforme
  69. 2005

    Cannabis--psychosis pathway independent of other types of psychopathology

    DesfavorávelEnsaio ClínicoPsicoseTetraidrocanabinol (THC)
  70. 2005

    Cannabis-induced Cytotoxicity In Leukemic Cell Lines: The Role Of The Cannabinoid Receptors And The MAPK Pathway

    FavorávelEstudo LaboratorialCâncerCâncer — LeucemiaTetraidrocanabinol (THC)
  71. 2005

    Cardiovascular complications induced by cannabis smoking: a case report and review of the literature

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDoenças Cardiovasculares (DCV)Infarto+2
  72. 2005

    CB1 receptor antagonists for the treatment of nicotine addiction.

    FavorávelEstudo em AnimaisDependência QuímicaDependência — NicotinaCanabinoides Sintéticos SR-x
  73. 2005

    Co-administration of THC and MDMA (‘Ecstasy’) Synergistically Disrupts Memory in Rats

    FavorávelEstudo em AnimaisEfeitos Adversos da CannabisDisfunção Cognitiva
  74. 2005

    Comparison of Cannabidiol, Antioxidants, and Diuretics in Reversing Binge Ethanol-Induced Neurotoxicity.

    FavorávelEstudo em AnimaisDependência QuímicaDisfunção CognitivaEstresse Oxidativo+3
  75. 2005

    Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

    DesfavorávelMetanáliseFibroseHepatiteFibrose — Hepática (Cirrose)
  76. 2005

    Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting

    FavorávelEstudo em AnimaisCâncerNáusea e Vômito
  77. 2005

    Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction

    DesfavorávelEnsaio Clínico Duplo-CegoEsquizofreniaTHC Farmacêutico
  78. 2005

    Delta9-tetrahydrocannbinol Accounts for the Antinociceptive, Hypothermic, and Cataleptic Effects of Marijuana in Mice

    FavorávelEstudo em AnimaisDorEpilepsiaDor — AgudaTetraidrocanabinol (THC)THC Farmacêutico+2
  79. 2005

    Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)

    FavorávelMetanáliseDepressãoDoença de Parkinson
  80. 2005

    Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin

    FavorávelEstudo LaboratorialInflamaçãoSíndrome de Ativação Mastocitária
  81. 2005

    Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood

    FavorávelEnsaio ClínicoHIV/AIDSTHC Farmacêutico
  82. 2005

    Dronabinol, a possible new therapeutic option in patients with COPD and pulmonal cachexia

    FavorávelEnsaio ClínicoAnorexia (perda de apetite)CaquexiaPerda de Apetite+1
  83. 2005

    Ecstasy/MDMA and cannabis: The complexities of their interactive neuropsychobiological effects

    FavorávelMetanáliseEfeitos Adversos do MDMA
  84. 2005

    Effects of cannabinoid treatment on Chagas disease pathogenesis: balancing inhibition of parasite invasion and immunosuppression

    FavorávelEstudo em AnimaisDoença de ChagasCanabinoides Sintéticos WIN-x
  85. 2005

    Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

    DesfavorávelEnsaio Clínico Duplo-CegoDoenças Cardiovasculares (DCV)ObesidadeCanabinoide Sintético (não especificado)
  86. 2005

    Efficacy of dietary hempseed oil in patients with atopic dermatitis

    FavorávelEnsaio ClínicoDermatite de Contato AlérgicaEczema
  87. 2005

    Endocannabinoid signaling in stress, medicine and wellness

    FavorávelMetanáliseLongevidadeEndocanabinoide (não especificado)
  88. 2005

    Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood

    FavorávelMetanáliseGestaçãoAnorexia (perda de apetite)Anorexia NervosaEndocanabinoide (não especificado)
  89. 2005

    Endocannabinoids In The Regulation Of Appetite And Body Weight

    FavorávelEstudo LaboratorialSíndrome MetabólicaAnorexia (perda de apetite)CaquexiaEndocanabinoide (não especificado)+1
  90. 2005

    Essential oil composition and antimicrobial activity of Diplotaenia damavandica.

    FavorávelEstudo LaboratorialInfecções Bacterianas
  91. 2005

    Ethanol Self-administration And Ethanol Conditioned Place Preference Are Reduced In Mice Lacking Cannabinoid CB1 Receptors

    FavorávelEstudo em AnimaisDependência QuímicaDependência — ÁlcoolCanabinoides Sintéticos SR-x
  92. 2005

    General and oral health implications of cannabis use

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDoença PeriodontalCáriesTetraidrocanabinol (THC)
  93. 2005

    Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin.

    FavorávelEstudo em AnimaisDorDor — Polineuropatia Inflamatória
  94. 2005

    Inhibition of Acetylcholinesterase Activity by Bicyclic Monoterpenoids

    FavorávelEstudo LaboratorialDisfunção CognitivaDoenças Neurodegenerativas
  95. 2005

    Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling

    FavorávelEstudo em Animais2-Araquidonoilglicerol (2-AG)Canabinoides Sintéticos SR-x
  96. 2005

    Integration Of Endocannabinoid And Leptin Signaling In An Appetite-related Neural Circuit

    FavorávelEstudo em AnimaisAnorexia (perda de apetite)Anandamida (AEA)
  97. 2005

    Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies.

    FavorávelMetanáliseDorDor — Neuropatia PeriféricaDor — Polineuropatia InflamatóriaOutros Compostos Relacionados
  98. 2005

    Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine.

    FavorávelEstudo LaboratorialHIV/AIDSAnandamida (AEA)Outros Compostos Relacionados
  99. 2005

    Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids

    InconclusivoEnsaio Clínico Duplo-CegoCanabicromeno (CBC)
  100. 2005

    Novel treatment for cough

    FavorávelMetanáliseTosseAnandamida (AEA)Canabinoide Sintético (não especificado)